Latest MedImmune Stories
The vaccine based on Cytos' Virus-Like Particle technology may open the door to accelerated production of influenza vaccines in SingaporeSingapore and Schlieren (Zurich), Switzerland, May 17, 2013 - (ACN Newswire) - Singapore's Agency for Science, Technology and Research (A*STAR) and Switzerland's Cytos Biotechnology AG today announced that the first healthy volunteer has been dosed in a Phase 1 clinical trial with their H1N1 influenza vaccine candidate based on Cytos'...
NES ZIONA, Israel, May 13, 2013 /PRNewswire/ -- NanoPass Technologies Ltd. ("NanoPass"), a pioneer in intradermal (into-the-skin or ID) vaccine delivery solutions, is collaborating with the US Center of Disease Control and prevention (CDC) in conducting a large phase 3 trial of polio vaccine in infants in South East Asia. This collaboration is a part of NanoPass's long-term commitment to improve Global Health by providing access to its vaccine delivery devices....
GAITHERSBURG, Md., May 4, 2013 /PRNewswire/ -- MedImmune announced today it will conduct seven poster and/or presentations at the Pediatric Academic Societies (PAS) Meeting at the Walter E. Washington Convention Center in Washington DC, May 4-7, 2013. These abstracts advance the body of existing data and knowledge around influenza and respiratory syncytial virus (RSV) prevention, highlighting MedImmune's continued commitment to patient health. MedImmune posters to be presented at...
Ready to Manufacture a Vaccine for the H7N9 Influenza Virus MERIDEN, Conn., May 2, 2013 /PRNewswire/ -- Protein Sciences announced today that it had completed development of the vector required to manufacture a vaccine to protect against the new and deadly H7N9 Bird Flu and is prepared to commence manufacturing within a few days of receiving orders for the vaccine. It has been possible to move quickly and safely to develop the H7N9 vaccine because we use modern, proprietary,...
BEIJING, April 30, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccine products in China, announced today that it has filed its 2012 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2012 on April 30, 2013. The Annual Report on Form 20-F is now available on the Company's website under SEC Filing in the Investor Relations section. The Company will provide a hard copy of its complete audited...
SAN DIEGO, Calif. and OXFORD, England, April 30, 2013 /PRNewswire/ -- Glide Pharma(®) today announced the award of a sub-contract from Pfenex Inc. to develop a solid formulation containing the recombinant Protective Antigen (rPA) from Bacillus anthracis expressed in Pfenex Expression Technology(TM) suitable for delivery with the Glide SDI(® )(solid dose injector). This approach will address two important logistical constraints of the currently available vaccine, namely, long term...
BEIJING, April 18, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccines in China, announced today that it has received the Certificate of Approval to commercialize seasonal flu vaccine in Mexico by the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) of the Mexico Ministry of Health. The certificate of commercial approval is valid from April 1, 2013 to April 1, 2018. The Company filed the application to distribute Anflu in...
PROVIDENCE, R.I., April 13, 2013 /PRNewswire/ -- Full Story - http://bit.ly/H7N9EpiVax The H7N9 emerging from China is a stealth virus. State of the art bioinforamatics tools have enabled EpiVax to predict that it will be hard to make vaccines and diagnostics for the new H7N9 flu virus (also called H7N9A/Shanghai/1/2013). H7N9 has fewer T cell epitopes than most previously circulating strains of flu, meaning that it may be able to fly under the immune system's radar. Making a rapid...
QUEBEC CITY, March 28, 2013 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced its operational and financial results for the fourth quarter and year ended December 31, 2012. The Company's financial statements and management report are available at www.sedar.com and at www.medicago.com. "2012 was a...
BLUE BELL, Pa., March 18, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE AMEX: INO) today reported financial results for the fourth quarter and year ended December 31, 2012. Total revenue was $1.1 million and $4.1 million for the quarter and year ended December 31, 2012, compared to $1.6 million and $9.8 million for the same periods in 2011. Total operating expenses for the quarter and year and ended December 31, 2012, were $7.4 million and $27.6 million as compared to $7.4...
